ClinicalTrials.Veeva

Menu

A Local Experiential Study With Sitagliptin (an Antihyperglycemic Drug) in 30 Patients With Type 2 Diabetes Mellitus (0431-178)

Merck Sharp & Dohme (MSD) logo

Merck Sharp & Dohme (MSD)

Status and phase

Completed
Phase 3

Conditions

Type 2 Diabetes

Treatments

Drug: Sitagliptin phosphate
Drug: Metformin

Study type

Interventional

Funder types

Industry

Identifiers

NCT01034111
2009_705
0431-178

Details and patient eligibility

About

This study will assess, over a 4-week treatment period, the safety and efficacy of the addition of sitagliptin to metformin in participants with type 2 diabetes mellitus (T2DM) who failed to achieve glycemic control on metformin monotherapy.

Enrollment

30 patients

Sex

All

Ages

18 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Participants with T2DM failing metformin monotherapy
  • Between the ages of 18 and 79

Exclusion criteria

  • Participants has a history of type 1 Diabetes Mellitus or ketoacidosis

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

Sitagliptin
Experimental group
Description:
Sitagliptin as add-on therapy to a stable dose of metformin
Treatment:
Drug: Metformin
Drug: Sitagliptin phosphate

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems